Front: Dr. Norman Chan; Back from left: Dr. Wong Shue Ngar Sheila, Mr. Tsang Hing Shun Thoman and Ms. Katherine Tsang.

Our promoters are Dr. Norman Chan, Ms. Katherine Tsang and Max Giant Limited. All of our Class B ordinary shares are held by Hong Kong Acquisition Company Limited, which is owned as to 51% by Extra Shine Limited (which is wholly owned by Dr. Norman Chan), 32% by Pride Vision Group Limited (which is wholly owned by Ms. Katherine Tsang) and 17% by Max Giant Limited (which is a fully accredited licensed entity by the SFC holding a Type 9 license (Asset Management) and a Type 4 license (Advising on Securities)).

Dr. Norman Chan

Dr. Norman Chan has a long and distinguished career in banking and finance, having served as the Deputy Director (Monetary Management) of the Office of the Exchange Fund in 1991, the Executive Director of the Hong Kong Monetary Authority (the “HKMA”) in 1993, the Deputy Chief Executive of the HKMA from 1996 to 2005, Vice Chairman, Asia, of the Standard Chartered Bank from December 2005 to June 2007 and the Chief Executive of the HKMA from October 2009 to September 2019. Having helped establish the HKMA in 1993, he personally directed and commanded the stock market operation of the HKSAR Government in August 1998 during the Asian Financial Crisis. In 1999, he led the launch of the initial public offering of the Tracker Fund of Hong Kong (stock code: 2800) on the Main Board of The Stock Exchange of Hong Kong as the means to dispose of part of the stocks that the Exchange Fund had purchased during the stock market operation.

As Chief Executive of the HKMA, Dr. Norman Chan strived to maintain, in addition to banking, monetary and financial stability in Hong Kong, the competitive position of Hong Kong as the premier international financial center. He had spearheaded numerous important market infrastructure projects such as the interbank Real Time Gross Settlement System and the Hong Kong Mortgage Corporation (which has helped develop the markets in mortgage securitization, mortgage insurance and life annuity etc. in Hong Kong). He also played a crucial role in promoting Hong Kong as the international hub of offshore Renminbi businesses as well as developing special capital market linkages between Hong Kong and mainland China, such as the Stock Connect and Bond Connect.

Dr. Norman Chan is a staunch supporter of financial inclusion and innovation. In 2013, he launched the Treat Customers Fairly Charter for banks in Hong Kong. In 2017, he launched the Smart Banking campaign, which includes seven initiatives such as the Faster Payment System, Virtual Banks, Open API etc. Dr. Norman Chan has also recently founded two fintech companies with the mission to develop workable solutions to address the pain points of small and medium-sized enterprises in cross border payment and in accessing banking services.

Ms. Katherine Tsang

Ms. Katherine Tsang is a well-recognized member of the Asian financial and business community. She is well known for her business acumen during her 22-year tenure in Standard Chartered Bank, achieving outstanding successes that earned her many first-in-the-role as a woman as well as being an Asian. In 2014, she found Max Giant Group, an asset management business that has established a host of funds.

Ms. Tsang started her career in Standard Chartered Bank in 1992 in the global securities custodian division Equitor and had since been trusted with different regional and global positions, with the last ten years appointed to lead Standard Chartered Bank’s business in China and Greater China, respectively. From investment and founding of Bohai Bank in Tianjin China in 2005 to the Pre-IPO investment in Agricultural Bank of China in 2010, Ms. Katherine Tsang had worked on and led mergers and acquisitions of several major financial institutions during the past two decades.

At the helm of the bank’s China business from 2004 to 2009, Ms. Tsang led Standard Chartered Bank’s growth from a network of 11 to more than 50 outlets in 17 cities, delivering a 10-fold revenue increase.

Ms. Katherine Tsang is currently an independent non-executive director of Fosun International Limited (listed on the Hong Kong Stock Exchange with stock code: 656), an independent non-executive director of Budweiser Brewing Company APAC Limited (listed on the Hong Kong Stock Exchange with stock code: 1876), an independent non-executive director of Fidelity Emerging Markets Limited (listed on London Stock Exchange with stock code: GSS), an independent non-executive director of China CITIC Bank International Limited.

Max Giant Limited

Max Giant is a licensed corporation licensed by the SFC to conduct Type 4 (Advising on Securities) and Type 9 (Asset Management) regulated activities. It was co-founded by Ms. Katherine Tsang, Dr. Wong Shue Ngar Sheila and Mr. Tsang Hing Shun Thomas in 2014.

Max Giant manages a host of private equity funds and investment projects for Max Giant Group and client that focus on China and Asia with an environmental, social, and governance (ESG) bias.

Max Giant focuses on its area of strengths in Greater China and managed the investments in a number of renowned companies globally in the finance, technology, life science and healthcare sectors. Some examples of such portfolio companies include:

  • Eat Just, Inc., a company that applies cutting edge science and technology to create healthier and more sustainable foods. The company created “Just Egg”, which is made entirely from plants. From being one of the fastest-growing egg brands in the North American markets, it has become a global leader in the sector. The Company has also created “Good Meat”, the world’s first regulatory approved as well as first-to-market meat made from animal cells instead of slaughtered livestock. Just Eat Inc. has been recognised as one of the Fast Company’s “Most Innovative Companies”, Entrepreneur’s “100 Brilliant Companies”, CNBC’s “Disruptor 500” and a World Economic Forum Technology Pioneer.
  • NeuSoft Medical Systems Co., Ltd, a leading global clinical diagnosis and treatment solution provider based in China that develops and manufactures CT, MRI, PET/CT and other clinical imaging equipment and solutions. With 41,000 installations in more than 110 countries, it offers advanced medical imaging technology and solutions to patients and healthcare providers around the world.
  • L&C Bioscience Technology (Kunshan) Co., Ltd., a subsidiary of L&C Bio Co., Ltd., a top life science and biotechnology group in Asia that specializes in human tissue implant materials, medical devices based on human tissues prescription drugs and cosmetics.
  • Hong Kong Medical Consultants Limited, a medical and healthcare service provider based in Hong Kong, aiming to provide seamless and comprehensive medical services to Hong Kong as well as clients in the Greater Bay Area. Its medical services include multi-disciplinary clinical specialist consultations, various aspects of medical care and disease prevention including health checks and diagnoses, and introduction of allied professional services such as speech therapy, physiotherapy, occupational therapy, clinical psychology, nutritionist service, and traditional Chinese Medicine with special interests in acupuncture, oncology and medicinal food supplementation.

Max Giant plays a critical role in the establishment of our Company. It applies its professional expertise and network to initiate the set-up of our Company, and stands ready to participate in the sourcing and screening of De-SPAC targets, as well as the execution of the subsequent De-SPAC transaction.